Author:
Awasthi Mayanka,Macaluso Anthony,Myscofski Dawn,Prigge Jon,Koide Fusataka,Noyce Ryan S,Fogarty Siobhan,Stillwell Helen,Goebel Scott J,Daugherty Bruce,Nasar Farooq,Bavari Sina,Lederman Seth
Abstract
AbstractTNX-1800 is a synthetically derived live chimeric Horsepox Virus (rcHPXV) vaccine expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy of TNX-1800 in two nonhuman primate species challenged with USA-WA1/2020 SARS-CoV-2. TNX-1800 vaccination was well tolerated, as indicated by the lack of serious adverse events or significant changes in clinical parameters. A single dose of TNX-1800 generated robust humoral responses in African Green Monkeys and Cynomolgus Macaques, as measured by the total binding anti-SARS-CoV-2 S IgG and neutralizing antibody titers against the USA-WA1/2020 strain. In Cynomolgus Macaques, a single dose of TNX-1800 induced a strong interferon-gamma (IFN-γ) mediated T cell response, promoting both pathogen clearance in the upper and lower airways and generation of systemic neutralizing antibody response against WA strain SARS-CoV-2. Future studies will assess the efficacy of TNX-1800 against newly emerging variants and demonstrate its safety in humans.
Publisher
Cold Spring Harbor Laboratory
Reference25 articles.
1. WHO Coronavirus Disease (COVID-19) Dashboard, https://covid19.who.int/. (accessed 2023-05-9).
2. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment
3. Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis
4. Why vaccines matter: understanding the broader health, economic, and child development benefits of routine vaccination;Hum Vaccin Immunother,2020
5. Vaccination greatly reduces disease, disability, death and inequity worldwide
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献